Dna repair drugs are used to treat genetic disorders caused due to errors in dna repair mechanisms. These drugs help in rectifying errors in dna strands and sequences thereby helping in treating complex conditions like cancer and genetic disorders. Their ability to repair damaged dna and restore proper dna functioning makes them highly effective therapeutic agents.

The global Dna Repair Drugs Market is estimated to be valued at US$ 6.28 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the major trends driving the growth of the dna repair drugs market is the increasing incidence of cancer worldwide. According to WHO, cancer burden has risen to 18.1 million new cases and 9.6 million deaths in 2018. The four main types of cancer with highest incidents being lung, breast, colon and prostate cancer. DNA repair pathways play a critical role in preventing cancer formation. Malfunctions in DNA repair pathways leads to accumulation of DNA damage which drives the cancer development and progression. Therefore, effective DNA repair drugs are developed which target specific DNA repair pathways dysfunctional in cancer cells thereby inhibiting tumor growth and progression.
 

Segment Analysis
The global DNA repair drugs market size is segmented into directed drugs, and organic small molecules. The directed drugs segment dominated the market in 2022 and is expected to continue its dominance over the forecast period owing to the availability of drugs like Polynucleotide kinase 3'-phosphatase (PNKP), XRCC1, and PARP inhibitors that are specifically directed towards repairing DNA.

Key Takeaways
The global DNA repair drugs market is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing incidence of cancer globally.

Regional analysis
North America dominated the global market in 2022 and is expected to continue its dominance over the forecast period. This is attributed to the growing prevalence of cancer and rising healthcare spending in the region. Asia Pacific is expected to witness the highest growth rate over the forecast period owing to rising cancer incidence, growing awareness regarding cancer treatment, and increasing healthcare expenditure in the region.

Key players
Key players operating in the DNA repair drugs market are AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Merck KGAA, Novartis AG, Pfizer Inc., and Sanofi S.A.

Get more insights on this topic: https://www.newsstatix.com/dna-repair-drugs-market-share-and-opportunity-analysis-2023-2030/